scholarly journals Argon–Helium Cryoablation for Cutaneous Squamous Cell Carcinoma in the Elderly

2022 ◽  
Vol 11 ◽  
Author(s):  
Qianwen Huang ◽  
Wenshen Xu
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Malignant Neoplasm ◽  
The Elderly ◽  
Cutaneous Squamous Cell Carcinoma ◽  
Surgical Removal ◽  
Non Melanoma Skin Cancer ◽  
Good Cosmetic ◽  
Cosmetic Outcomes

Cutaneous squamous cell carcinoma (cSCC) is a common type of malignant neoplasm in non-melanoma skin cancer (NMSC). Most cases of simple cSCC are considered curable by surgical removal of the lesion. However, clinical treatments for cSCC with medium- or large-sized lesions are difficult. Meanwhile, the effectiveness of the treatments is not guaranteed, especially for elderly patients, because of an intolerance to surgical resection or other adjuvant modalities. In such cases, safe and effective treatments with excellent aesthetic outcomes are urgently needed. In this study, we reported 6 elderly cSCC patients with medium- or large-sized lesions treated with argon–helium cryoablation. The average age of all 6 patients was 78 years (range 72–85 years). They were all diagnosed with cSCC with a median tumor size of 5.8 cm (range 2.5–15.5 cm) and dermal invasion. Complete ablation was achieved in all cases after a single ablation session (2 freeze–thaw cycles). Patients experienced mild pain and hemorrhage after ablation, but the symptoms were manageable. One patient developed infection and fever because of extensive necrosis of the tumor, which was eventually cured after treatment. All patients obtained good cosmetic outcomes, and their quality of life improved significantly. In the 5-year follow-up study, 4 patients were alive while 2 patients died of unrelated diseases 3 years after cryotherapy. None of the 6 patients had a recurrence. These results suggested the feasibility of argon–helium cryoablation as a novel therapeutic strategy for elderly cSCC with medium- or large-sized lesions.

scholarly journals Dramatic radiotherapy response of a giant T4 cutaneous squamous cell carcinoma of the scalp with extensive bone destruction: a case report

2021 ◽  
Vol 15 (1) ◽  
Author(s):  
Isabella Gruber ◽  
Oliver Koelbl
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Antibody Therapy ◽  
Bone Destruction ◽  
Complete Response ◽  
Cutaneous Squamous Cell Carcinoma ◽  
Secondary Intention ◽  
Sagittal Sinus ◽  
Good Cosmetic

Abstract Background Patients with large cutaneous squamous cell carcinoma of the scalp are a treatment challenge. We report a case of dramatic radiotherapy response of a patient with a giant cutaneous squamous cell carcinoma of the scalp with extensive skull destruction and suspected infiltration of the dura mater and superior sagittal sinus. This case is the first report of this kind in the literature that shows that large bone defects can heal with the resolution of tumor and inflammation by secondary intention without surgical reconstruction. We want to put an end to concerns about radiocurability of tumors with extensive bone involvement, and show sustained complete response after definitive radiotherapy and programmed cell death protein-1 inhibiting antibody therapy. Case presentation A 74-year-old White man presented with a 7.2 × 6.8 × 5.5 cm painless tumor on the right parietal region of the scalp. Medical imaging revealed widespread destruction of the skull and suspected infiltration of the dura mater and superior sagittal sinus. Biopsies showed cutaneous squamous cell carcinoma (cT4a cN0 cM0, stage IVA). The patient was treated with a total dose of 60 Gy, at 2 Gy per daily fraction with volumetric modulated arc therapy using 6 megavoltage photons. The biologically effective dose (alpha/beta 10 Gy) was 72 Gy. The tumor response correlated with dose received. The patient had a massive tumor necrosis secondary to tumor shrinkage after 18 fractions (36 Gy, biologically effective dose 43.2 Gy). Leakage of cerebrospinal fluid did not occur. Radiotherapy did not hamper the patient’s quality of life. The patient had a clear regression of the initial tumor on the final day of radiotherapy. The bone defect healed by secondary intention without surgical interventions. The patient achieved a complete response with a good cosmetic result after 82 days follow-up. He started a programmed cell death protein-1 inhibiting antibody therapy with cemiplimab 2 months after radiotherapy, and is now at 10 months follow-up without evidence of recurrence. Conclusion Definitive radiotherapy is a safe and highly effective therapy for giant tumors of the scalp with extensive bone destruction. We report a sustained complete response with a good cosmetic result after secondary wound healing.

CUTANEOUS SQUAMOUS CELL CARCINOMA- A CASE REPORT

2021 ◽  
pp. 28-29
Author(s):  
Suprajha K.S. ◽  
Manimaran Manimaran ◽  
Barathiraja Barathiraja
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Malignant Neoplasm ◽  
Cutaneous Squamous Cell Carcinoma ◽  
Diagnostic Challenge ◽  
Diagnostic Uncertainty ◽  
The Past ◽  
Proliferative Growth ◽  
Well Differentiated

Cutaneous squamous cell carcinoma (cSCC) is a malignant neoplasm of the skin characterized by an aberrant 1 proliferation of keratinocytes. The usual presentation of skin malignancies include ulceration, growth, a change in mole, unusual form or bleeding due to various etiological factors. There exists a diagnostic challenge, as many benign conditions present similarly, thereby altering the treatment strategy. 2 Although Cutaneous Squamous Cell Carcinoma usually display a benign clinical behaviour, it can be both locally invasive and metastatic Here we report a case of an elderly female who presented with a proliferative growth in right forearm for the past 1 year, from a pre-existing mole, which on examination had features of all the three cutaneous malignancies resulting in a diagnostic uncertainty and which on further workup was diagnosed as a well differentiated squamous cell carcinoma

scholarly journals Increased Expression of Flightless I in Cutaneous Squamous Cell Carcinoma Affects Wnt/β-Catenin Signaling Pathway

2021 ◽  
Vol 22 (24) ◽  
pp. 13203
Author(s):  
Gink N. Yang ◽  
Xanthe L. Strudwick ◽  
Claudine S. Bonder ◽  
Zlatko Kopecki ◽  
Allison J. Cowin
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Cell Line ◽  
Signaling Pathway ◽  
Squamous Cell ◽  
Cancer Metastasis ◽  
Cellular Proliferation ◽  
Cutaneous Squamous Cell Carcinoma ◽  
Negative Regulator ◽  
Surgical Removal

Cutaneous squamous cell carcinoma (cSCC) accounts for 25% of cutaneous malignancies diagnosed in Caucasian populations. Surgical removal in combination with radiation and chemotherapy are effective treatments for cSCC. Nevertheless, the aggressive metastatic forms of cSCC still have a relatively poor patient outcome. Studies have linked actin cytoskeletal dynamics and the Wnt/β-catenin signaling pathway as important modulators of cSCC pathogenesis. Previous studies have also shown that the actin-remodeling protein Flightless (Flii) is a negative regulator of cSCC. The aim of this study was to investigate if the functional effects of Flii on cSCC involve the Wnt/β-catenin signaling pathway. Flii knockdown was performed using siRNA in a human late stage aggressive metastatic cSCC cell line (MET-1) alongside analysis of Flii genetic murine models of 3-methylcholanthrene induced cSCC. Flii was increased in a MET-1 cSCC cell line and reducing Flii expression led to fewer PCNA positive cells and a concomitant reduction in cellular proliferation and symmetrical division. Knockdown of Flii led to decreased β-catenin and a decrease in the expression of the downstream effector of β-catenin signaling protein SOX9. 3-Methylcholanthrene (MCA)-induced cSCC in Flii overexpressing mice showed increased markers of cancer metastasis including talin and keratin-14 and a significant increase in SOX9 alongside a reduction in Flii associated protein (Flap-1). Taken together, this study demonstrates a role for Flii in regulating proteins involved in cSCC proliferation and tumor progression and suggests a potential role for Flii in aggressive metastatic cSCC.

Evaluation of the Treatment of Head and Neck Cutaneous Squamous Cell Carcinoma in the Elderly: A Survival Analysis

2018 ◽  
Vol 96 (9) ◽  
pp. 577-582
Author(s):  
Álvaro Jesús Bernal Martínez ◽  
Nieves Fernández Letamendi ◽  
Julio Delgado Martínez ◽  
Lucía Gómez-Escolar Larrañaga ◽  
Enara Reola Ramírez ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Survival Analysis ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
The Elderly ◽  
Cutaneous Squamous Cell Carcinoma

scholarly journals Immune Checkpoint Blockade in Advanced Cutaneous Squamous Cell Carcinoma: What Do We Currently Know in 2020?

2020 ◽  
Vol 21 (23) ◽  
pp. 9300
Author(s):  
Anja Wessely ◽  
Theresa Steeb ◽  
Ulrike Leiter ◽  
Claus Garbe ◽  
Carola Berking ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Immune Checkpoint ◽  
Immune Checkpoint Blockade ◽  
Cutaneous Squamous Cell Carcinoma ◽  
Checkpoint Blockade ◽  
Field Cancerization ◽  
Current Evidence ◽  
Surgical Removal

Cutaneous squamous cell carcinoma (cSCC) is the second most common skin cancer that predominantly arises in chronically sun-damaged skin. Immunosuppression, genetic disorders such as xeroderma pigmentosum (XP), exposure to certain drugs and environmental noxae have been identified as major risk factors. Surgical removal of cSCC is the therapy of choice and mostly curative in early stages. However, a minority of patients develop locally advanced tumors or distant metastases that are still challenging to treat. Immune checkpoint blockade (ICB) targeting CTLA-4, PD-L1 and PD-1 has tremendously changed the field of oncological therapy and especially the treatment of skin cancers as tumors with a high mutational burden. In this review, we focus on the differences between cSCC and cutaneous melanoma (CM) and their implications on therapy, summarize the current evidence on ICB for the treatment of advanced cSCC and discuss the chances and pitfalls of this therapy option for this cancer entity. Furthermore, we focus on special subgroups of interest such as organ transplant recipients, patients with hematologic malignancies, XP and field cancerization.

Sign in / Sign up

Export Citation Format

Share Document